top of page

EMA - Guideline on Treatment of Bacterial Infections

European Medicines Agency (EMA) has issued a final guideline on evaluating antibacterial medicines that follow the guidelines of other regulators globally.


This guideline merges, revises, and adds to the guidance previously included in the guideline on the evaluation of medicinal products indicated for the treatment of bacterial infections (CPMP/EWP/558/95 Rev 2) and the Addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections (EMA/CHMP/351889/2013).

In the face of increasing problems posed by bacterial resistance, there is a pressing need for new antibacterial agents suitable for treating infections in patients with few remaining therapeutic options.


This guideline will facilitate clinical development programs for new antibacterial agents and support modifications to the uses and/or regimens for licensed agents there is a need to ensure that each clinical trial conducted can be designed to meet the requirements of multiple regulatory agencies.


The guideline is relevant to antibacterial agents with a direct action on bacteria resulting in inhibition of replication leading to bacterial cell death.


The guidance includes antibacterial agents administered systemically (including oral administration to treat pathogens that are confined to the gastrointestinal tract) or formulated for topical administration to the skin.


Specific guidance is not provided on the development of antibacterial agents formulated for topical

administration to the ears and eyes or for inhalation, although many of the general principles are applicable.


Click on the LINK to know more about this guidance.

Recent Posts

See All

Comments


I Sometimes Send Newsletters

Thanks for submitting!

  • LinkedIn
  • Facebook
  • Twitter
  • Instagram

DISCLAIMER

The views expressed in this publication do not necessarily reflect the views of any guidance of government, health authority, it's purely my understanding. This Blog/Web Site is made available by a regulatory professional, is for educational purposes only as well as to give you general information and a general understanding of the pharmaceutical regulations, and not to provide specific regulatory advice. By using this blog site you understand that there is no client relationship between you and the Blog/Web Site publisher. The Blog/Web Site should not be used as a substitute for competent pharma regulatory advice and you should discuss from an authenticated regulatory professional in your state.  We have made every reasonable effort to present accurate information on our website; however, we are not responsible for any of the results you experience while visiting our website and request to use official websites.

bottom of page